Our LLM-enabled precision oncology approach can inform more effective treatment strategies for RGT patients and suggests the potential for incorporating biomarkers, such as PD-L1 expression, to broaden therapeutic options and inform more personalized strategies that transcend traditional organ-based boundaries, particularly in the context of cancers with limited standard treatments. Here, CD274 is linked to cancer.